The four signals that decide how fast you age
Aging is governed by four ancient signaling pathways that your body already speaks. Understanding them is the first step to speaking back.
Most longevity advice asks you to chase molecules. The smarter move is to understand the conversation your cells are already having. Four ancient signaling pathways negotiate your rate of aging every day. Here is what they say, how they say it, and why the signal matters more than the supplement.
If you have spent any time in the longevity space, you have heard the names. mTOR. AMPK. Sirtuins. IGF-1. They get thrown around in podcast intros and supplement labels like everybody already knows what they mean, which is the first problem, because most people do not. The second problem is worse. The typical framing treats each pathway as an independent dial you can turn up or down with the right molecule, which is a misunderstanding deep enough to lead people to interventions that cancel each other out.1
The four pathways form a single negotiation that has been running inside your cells for roughly two billion years.
The four pathways form a single negotiation that has been running inside your cells for roughly two billion years.
Think of them as a cellular parliament with four ancient committees. One committee tracks whether nutrients are available. Another monitors energy status. A third reads stress signals and decides what gets repaired. The fourth manages the growth-and-repair budget. Each committee has a vote, and the outcome of their continuous negotiation is, in a literal sense, how fast you age.
This is a map of the conversation, not a supplement guide.
I · mTOR
mTOR stands for mechanistic target of rapamycin. The name is a historical accident, born of rapamycin’s affinity for the protein, but the function is ancient and deliberate. mTOR is your cell’s primary nutrient sensor, and it has been doing this job since before animals existed. Fungi use it. Plants use it. Every eukaryote on Earth uses some version of this pathway to decide whether conditions are right for growth.
When mTOR complex 1 (mTORC1) is active, your cell is in build mode. Ribosomes assemble. Proteins get made. Lipids are synthesized. Autophagy, the cellular recycling program that clears damaged proteins and worn-out mitochondria, gets suppressed, because you do not tear down the factory while it is running at full capacity.
This is entirely appropriate when you are twenty and building muscle after a workout. It is a problem when mTORC1 stays active for decades. Chronic mTOR activation, driven by constant nutrient availability and sedentary living, drives the accumulation of senescent cells, low-grade inflammation, and the metabolic rigidity that underlies most age-related disease.
The most striking evidence for mTOR’s role in aging comes from the Interventions Testing Program, a multi-site NIH study designed to eliminate the kind of lab-specific artifacts that plague longevity research. In 2009, the ITP reported that rapamycin, an mTORC1 inhibitor, extended median lifespan in genetically heterogeneous mice by 9% in males and 13% in females when started at 600 days of age.2 That starting age corresponds to roughly 60 human years. The intervention began in late middle age, and it still worked.
Why constant feeding is an mTOR problem
mTORC1 is activated by amino acids, particularly leucine, and by growth factors like insulin and IGF-1. Every meal that contains protein sends a pulse of mTOR activation through your tissues. This is normal and necessary. What is not normal is the modern pattern: three to five protein-containing meals per day, snacks in between, and a feeding window that stretches from 7 a.m. to 10 p.m.
Leucine is the most potent amino acid activator of mTORC1. A single 30-gram serving of whey protein delivers roughly 3 grams of leucine, enough to trigger a substantial mTOR pulse. This is useful after resistance training. It may not be useful three times a day, every day, for decades.
The evolutionary context matters here. For most of human history, feast and famine alternated. mTOR was supposed to cycle on and off. The off periods, when nutrient scarcity dropped mTOR activity, were when autophagy kicked in and cellular housekeeping got done. Constant feeding removes the off period, and without it, damaged components accumulate because the cleanup crew never gets called.
What actually moves the needle
Protein restriction and time-restricted feeding are the two behavioral interventions with the strongest evidence for reducing chronic mTOR activation. Neither requires a prescription. Both require a departure from the default modern eating pattern, which is exactly why they are underused despite being free.
Rapamycin and its analogs (rapalogs) are the pharmacological route, and they are the most robustly validated longevity intervention in mammalian pharmacology. The ITP has now replicated rapamycin’s lifespan extension across multiple cohorts and dosing schedules. The effect is real and dose-dependent. But rapamycin is an immunosuppressant at the doses used in transplant medicine, and the long-term safety profile of low-dose, intermittent rapamycin in healthy humans is still an open question, not a settled one.
II · AMPK
If mTOR is the accelerator, AMPK is the fuel gauge. AMP-activated protein kinase detects the ratio of AMP to ATP inside the cell. When energy runs low and AMP rises, AMPK activates and reshapes cellular metabolism toward conservation and efficiency.
AMPK activation drives three outcomes that matter for aging: it inhibits mTOR (putting the brakes on growth when energy is scarce), it activates the autophagy machinery, and it stimulates mitochondrial biogenesis — the creation of new mitochondria. A cell with active AMPK is a cell that is cleaning house and building better energy infrastructure while waiting out the lean period.
The strongest physiological activator of AMPK is exercise. Every muscle contraction consumes ATP, which raises the AMP-to-ATP ratio. This is why exercise produces metabolic effects that are difficult to replicate pharmacologically — it activates AMPK in the exact tissues where it matters, through a mechanism that evolution has optimized over hundreds of millions of years.
Metformin and the pharmaceutical shortcut
Metformin, the most prescribed diabetes drug in the world, activates AMPK indirectly through mitochondrial inhibition. It is the most studied compound ever proposed as a longevity intervention, and the evidence is mixed. Rodent studies show lifespan extension in some models but not others. The TAME trial (Targeting Aging with Metformin) is ongoing and may provide the first human data on metformin’s geroprotective effects.3
The smart read on metformin is cautious. It works well for its intended population (people with metabolic syndrome) but may actually blunt the adaptive benefits of exercise in healthy individuals, because both exercise and metformin activate AMPK through different mechanisms that may not stack.4 If you already exercise, metformin may be redundant. If you do not, it is not a substitute.
III · Sirtuins
Sirtuins are a family of seven proteins (SIRT1 through SIRT7) that sit at the intersection of metabolism and gene expression. They are NAD+-dependent deacetylases, which means they remove acetyl groups from proteins, but the functional description that matters is simpler: sirtuins are the repair foremen of your cellular parliament.
When mTOR signals abundance and AMPK signals scarcity, sirtuins read the NAD+ level, which functions as a proxy for metabolic stress. High NAD+ activates sirtuins. Low NAD+ silences them. And since NAD+ levels decline naturally with age — by roughly 50% between age 20 and 60 — sirtuin activity falls off a cliff in mid-to-late life.5
SIRT1 activation can be seen as a defense against cellular aging, and its decline with age represents a loss of that defense.
Guarente L. The Sirtuin Hypothesis of Aging. Cell. 2011.
SIRT1, the most studied member of the family, deacetylates proteins involved in DNA repair, mitochondrial function, and inflammation control. It activates PGC-1alpha, the master regulator of mitochondrial biogenesis. It suppresses NF-kB, reducing inflammatory signaling. And it indirectly inhibits mTOR activity through the TSC1/TSC2 complex.
The NAD+ precursor problem
The supplement industry has seized on the NAD+ connection. NMN and NR, the two most popular NAD+ precursors, are among the best-selling longevity supplements on the market. The logic is seductive: NAD+ declines → sirtuins lose activity → raise NAD+ with precursors → restore sirtuin function.
The human data is not yet convincing. Oral NMN and NR do raise blood NAD+ levels, but the effect on tissue NAD+ is inconsistent. A 2023 randomized trial of NR (1 gram daily for 12 weeks) found no improvement in muscle NAD+ levels, mitochondrial function, or exercise capacity in older adults.6 The molecules reach the blood. Whether they reach the tissues in sufficient quantity to affect sirtuin activity is the unanswered question.
IV · IGF-1
Insulin-like growth factor 1 (IGF-1) is the signaling molecule that tells your cells to grow, divide, and stay alive. It is the primary mediator of growth hormone’s effects, and its signaling pathway is the most evolutionarily conserved longevity pathway known.
Reduced IGF-1 signaling extends lifespan in every model organism tested: yeast, worms, flies, and mice. The Ames dwarf mouse, which has a mutation that reduces IGF-1 levels, lives 50% longer than wild-type mice and remains cognitively and physically healthy well into advanced age.7 The effect is not subtle. It is one of the most robust findings in the biology of aging.
The growth hormone/IGF-1 axis is the most highly conserved longevity pathway. Reducing its activity extends lifespan across species, from C. elegans to mammals.
Kenyon C. The genetics of aging. Nature. 2010.
The human data comes from a natural experiment. Individuals with Laron syndrome, a condition that causes profound IGF-1 deficiency due to growth hormone receptor mutations, show dramatically reduced rates of cancer and diabetes despite living with a condition that is normally associated with increased mortality from other causes.8 They are protected against the two diseases that kill most people in developed countries.
Protein, mTOR, and the IGF-1 trade-off
IGF-1 signaling is directly activated by growth hormone, which is secreted in pulses, primarily during sleep. But IGF-1 is also modulated by protein intake through the mTOR pathway. High protein intake raises IGF-1 levels. Low protein intake lowers them. This creates a genuine trade-off: protein supports muscle mass and strength, but it also activates the IGF-1 signaling that drives aging in other tissues.
V · The negotiation
The reason the framework matters more than any single pathway is that these four signals are not independent. They form a network with specific cross-talk nodes, and intervening on one without understanding the others is how people end up taking supplements that work against each other.
AMPK activation inhibits mTOR. Sirtuins activate AMPK. IGF-1 activates mTOR. A supplement that raises NAD+ to boost sirtuins (good) may also indirectly lower IGF-1 signaling (also good), but if you are also taking leucine or HMB to spike mTOR for muscle growth, you are sending your cellular parliament contradictory instructions. The pathways do not negotiate with your intentions.
Exercise activates AMPK and suppresses mTOR during the activity itself. After exercise, mTOR rebounds and drives muscle protein synthesis. The net result is the best of both worlds: a pulse of autophagy during exercise, followed by a pulse of growth post-exercise. This temporal pattern — alternating activation and suppression — is what the pathways evolved to handle.
The concept of hormesis applies here: the same signal that is beneficial in pulses becomes harmful when chronically elevated. mTOR, AMPK, sirtuins, and IGF-1 all follow this pattern. The question is not whether a pathway is “good” or “bad.” The question is whether its activation pattern matches the one evolution designed it for.
A pathway that is turned on and off rhythmically produces health. A pathway that is locked in one position produces disease. Every longevity intervention worth considering is, at bottom, a strategy for restoring the rhythm.
The four-signal framework is not a supplement protocol. It is a lens for understanding why some interventions work, why others cancel each other out, and why the most powerful tool you have — exercise — manages to activate three of the four pathways in precisely the right temporal pattern, for free, with no side effects beyond sore muscles.
Every pathway in this essay has a dedicated monograph in the Aeterna Library. The references below are the primary sources — the actual papers, not the marketing summaries.
- This framing — the well patient asking a structural question — is discussed in the introduction to the Method. The distinction between reactive and proactive medicine is not new, but it has never been more actionable.
- Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395.
- Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab. 2016;23(6):1060-1065.
- Konopka AR, Esponda RR, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18(1):e12880.
- Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. A 50% decline by age 60 is consistent across multiple tissue types.
- Dollerup OL, Chubanava S, et al. Nicotinamide riboside does not alter mitochondrial respiration, content or exercise tolerance in older adults. Cell Metab. 2023;35(8):1466-1478.
- Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. Dwarf mice and the ageing process. Nature. 1996;384(6604):33.
- Guevara-Aguirre J, Balasubramanian P, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13.